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Vaccines) infections are generally long lasting, and a host immune response to infection
is hard to detect. Nevertheless immunocompromised subjects control HPV infection less well than those
with intact immunity. Immune responses are best documented for the papillomavirus groups that cause
evident human disease, particularly those responsible for anogenital cancers and genital warts. Humoral
immunity to the viral capsid has been shown sufﬁcient for protection against infection, while innate and
adaptive cell mediated immunity appears important for eventual elimination of HPV infection. However,
molecular and cellular mechanisms responsible for protection from and clearance of HPV infection are not
completely established.
© 2008 Elsevier Inc. All rights reserved.Host virus interactions: a primer
Viruses evolve to maximise reproductive ﬁtness in their host
(Marques and Carthew, 2007). Given time, mammalian viruses and
their host reach a state of equilibrium where the host is not greatly
disadvantaged in its reproductive capacity by virus infection, and the
virus is not too limited in reproductive capacity by the host immune
response. Papillomaviruses and their adapted mammalian hosts
appear to have reached that state of equilibrium over many
generations (Bernard, 2005). This paper will examine the mechanisms
used by papillomaviruses, and the host, to maintain that equilibrium.
Mammals have evolved sophisticated innate and adaptive
immune mechanisms to control local and systemic viral infection,
and to limit damage to the host where infection persists. Despite
these mechanisms, most papillomavirus infections are relatively long
lasting. How do papillomaviruses evade induction of host protective
immune responses? Triggering of innate immune mechanisms is a
key initiator of both innate and adaptive immune effector mechan-
isms for viral clearance. Triggers include double stranded RNAs, single
stranded DNAs, bacterial cell membrane components, intracellular
molecules released following unprogrammed cell death, and cell
membrane associated molecules displayed by distressed cells.
Papillomaviruses are double stranded DNA viruses that undergo
their vegetative reproductive cycle within, and in synchrony with,
squamous epithelial cells (Doorbar, 2005). They exit from mature
epithelial cells already programmed to undergo apoptosis, and are
shed to the environment. Thus, of the triggers to initiate an immune
response, only expression of membrane associated stress moleculesu.au.
l rights reserved.(Strid et al., 2008; Textor et al., 2008) would likely occur as a
consequence of disturbed cell cycle control. Further, negative
regulation of adaptive immunity is initiated by persisting presenta-
tion of PV antigen in epithelium (Doan et al., 2000) in the absence of
innate immune stimuli. Thus, the opportunity for papillomavirus
infection to induce speciﬁc immune mechanisms is limited.
Immune mechanisms controlling HPV infection
There are few data on the host immune interaction with the many
papillomaviruses not associatedwith evident disease. Their pathogenic
potential does not appear to be enhanced by immune deﬁciency,
though in immunosuppressed subjects some of the “non-pathogenic”
HPVs may be more easily detected in apparently normal skin sug-
gesting higher viral copy numbers, while other are associated with
immunodeﬁciency associated squamous cancers (Berkhout et al.,
2000; Asgari et al., 2008). Papillomaviruses commonly associated
with humandisease are arguably lesswell adapted to theirmammalian
host. There is a particular interest in the PVs designated high risk,
belonging to the clades (Chan et al., 1995) predisposing to cancer of the
skin (β1) and of the genital tract (α7,9). Study of the immune response
to these viruses is made difﬁcult by PV speciﬁcity for a single host
species, and by the limited range of systems for studying viral
reproduction in vitro. A successfully resolved prior infection with HPV
appears to protect against further infection with that HPV type.
Vaccines recently developed to prevent HPV16 and HPV18 associated
anogenital cancer consequent of persisting HPV infection induce
humoral immune responses to conformational epitopes on the
HPV16 and HPV18 viral capsid that are sufﬁcient to provide long
lasting protection against viral challenge (Kahn and Burk, 2007b).
However, the lower titre humoral immune responses to viral capsids
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particularly long lasting (Carter et al., 2000), do not correlate well with
detection of HPV DNA (Andersson et al., 2008), and their role in
prevention of further HPV infection is uncertain, particularly as anti-
body may not be necessary to provide protection against re-infection.
Although there are immunodeﬁciency syndromes in which persistent
warts are associated with hypogammaglobulinemia, these patients
always have impaired cellular immunity in addition (Hamblin, 2007;
Diaz and Gulino, 2005; Lawrence et al., 2005a; Reid et al., 1976;Wilson
et al., 1976); whereas, childrenwith simple agammaglobulinemia both
anecdotally and from the lack of published literature appear to be no
more prone than immunocompetent children to recurrent HPV
associated skin or genital warts. In contrast, subjects with persistent
cell mediated immune defects, whether due to HIV infection (Palefsky,
2007), persistent iatrogenic immunosuppression as therapy for
autoimmune disease or renal transplantation (Paternoster et al.,
2008; Ulrich et al., 2008), or congenital partial cellular deﬁciencies
(Lawrence et al., 2005b; Bernier-Buzzanga and Su, 1990) all are at
increased risk of persistence of infection with and disease caused by
pathogenic papillomaviruses, and associated cancers of the skin and
the anogenital tract. Interestingly individuals with compromised
cellular immunity do not appear to be at risk of new infection with
the common childhood wart virus infections, suggesting that the
memory response protecting against reinfection, whether antibody or
cell mediated, may not use the same components of the adaptive
immune system as the effector response necessary to control
persisting latent or vegetative infection. While impaired cellular
immunity hinders clearance of HPV infection, the 2% of infections
with high risk HPV that persist do so in apparently immunocompetent
individuals. There is nevertheless a substantial heritable component to
cervical cancer risk (Hemminki and Chen, 2006). Some genetic
determinants of risk of persisting HPV infection are deﬁned (Garcia-
Pineres et al., 2006) and these may include polymorphisms in genes
controlling the nature of effector T cell responses (Morahan et al.,
2002), as has been shown for other persistent viral infections (Yilmaz
et al., 2007; Hegazy et al., 2008).
The role of innate immunemechanisms in controllingHPV infection
is difﬁcult to determine from natural history studies, as most innate
immunemechanisms are necessary for embryogenesis or host survival,
and those that are not donot appear associatedwith an increased risk of
development of, or persistence of, skin or genital warts. An exception is
WHIM syndrome, characterised by absence of the chemokine receptor
CXCR4 and associated with poor neutrophil trafﬁcking and persistent
cutaneous warts (Gulino, 2003), suggesting a role for polymorpho-
nuclear phagocytes in clearance of HPV infection. Involvement of other
innate immune mechanisms, such as IFN release from NK cells, in
control of HPV infection can however be inferred from mechanisms
developed by papillomaviruses to evade them (Lee et al., 2001).
Measured immune responses to HPV infections
Viral capsid proteins
The most immunogenic component of pathogenic papilloma-
viruses is the major capsid protein, L1, assembled as 72 pentamers
into a virion. Binding of antibody to the viral capsid can bemeasured by
ELISA (Christensen et al.,1994) using virus like particles as substrate, or
by inhibition of binding of a labelled monoclonal antibody speciﬁc to a
capsid determinant (Opalka et al., 2003). Capacity for viral neutralisa-
tion can be assessed in vivo using puriﬁed virions and susceptible
target cells (Christensen and Kreider, 1990), or in vitro using
pseudovirions encoding a reporter gene expressible in a susceptible
target cell (Roden et al., 1996). Infection with a pathogenic papilloma-
virus produces a humoral immune response to the virus capsid which
recognises predominantly conformational determinants displayed
only when the L1 protein is correctly conﬁgured into pentamers as inthe native virus (Christensen et al., 1994). The adaptive immune res-
ponse to HPV is slower to appear than that to most pathogenic virus
infections (Carter et al., 2000). Antibody titres following natural in-
fection are low, and assays are difﬁcult to standardize (Ferguson et al.,
2005). For the well studied genital papillomaviruses (HPV 6,11, 16, and
18), mean times to seroconversion exceed 6 months, and 30–50% of
individuals with evidence of persisting genital HPV infection appear
never to acquire antibody (Carter et al., 2000). After clearance of viral
infection, viral capsid antibody titres fall. Nevertheless, about 50% of
HPV16 seropositive, HPV16 DNA −ve individuals will retain antibody
over 5–7 years (Wanget al., 2004). Clearance of antibodyafter infection
is not well documented for other virus types.Where infections persist,
antibody also appears to persist, andpatientswith cancers arising from
high risk genital HPV infections can have measurable viral capsid
antibody titresmany years after the infection that triggered the cancer,
though seropositivity for the cancerHPV type inpatientswith cancer is
generally reported at between 30% and 50% (Carter et al., 2001).
Antibody to the common skin papillomaviruses (HPV 1 and 2) is found
in 30% to 50% of children with warts, and with similar frequency in
unselected teenage children (Carter et al., 1993; Cubie et al., 1998).
Antibody to the viral capsid of the PVs causing cancer in the skin of
immunosuppressed patients (HPV5 and 8) however appears to be rare
in a healthy population (Favre et al., 1998). Thus, capsid antibody is
likely a measure of persisting HPV infection, though many with
infection do not have antibody, and disease site, viral load or local
inﬂammation may determine the extent to which antibody is pro-
duced. CD4+ T cell responses to capsid protein, necessary for optimal
antibody and cytotoxic T cell production, are also reported following
genital HPV infection, and are more evident in disease inﬁltrating
lymphocytes in the cervix than in the blood (Passmore et al., 2006;
Williams et al., 2002). The minor capsid protein L2 is immunogenic
during natural infection (Viladiu et al., 1997; Kanda et al.,1995) though
antibody to L2 within a virion after natural infection has been hard to
detect, perhaps because the relevant epitopes are only displayed after
virion binding to the cell surface (Day et al., 2008b).
Thus, capsid speciﬁc immune responses are of limited diagnostic
utility and seem unrelated to the process of viral clearance.
Viral non-structural proteins
Humoral immune responses to the 6 PV non-structural proteins
commonly expressed in disease associated human infection (E1, E2, E4,
E5, E6, and E7) have generally been measured using recombinant
fusionproteins or linear peptides. Themost consistent response is seen
in patients with cervical cancer associated with HPV16 infection, who
display antibody to the E7 protein (Jochmus-Kudielka et al.,1989),most
commonly with invasive and metastatic disease. Healthy adults and
patientswithHPV16 associated cervical intraepithelial neoplasia (CIN)
demonstrate positive skin test reactions, a measure of cellular
immunity, to E2, E6 and E7 peptides (van den et al., 2008). Cellular
immune responses are also evident in clinical disease as inﬁltrates
within lesions (van et al., 2008), though the proportion of T cells in
inﬁltrates speciﬁc for PV non-structural antigen is unknown. At the
time of genital wart regression, substantial mononuclear and other
cellular inﬁltrates can be demonstrated (Coleman et al., 1994).
Papillomavirus associated precancer lesions of the cervix (CIN 2/3)
have substantial T cell inﬁltrates whether disease regression appears
likely or not, as they are equally present in HIV+ve and HIV−ve indi-
viduals (Kobayashi et al., 2002). Similar inﬁltrates are found in cervical
cancer, and the ratio of CD4 to CD8 T cells appears to fall as HPV
associated lesions progress towards cancer (Monnier-Benoit et al.,
2006). CD4 cellular immune responses to two viral non-structural
proteins, E2 and E6, promote regression of warts caused by canine oral
papillomavirus (Jain et al., 2006). Similarly, CD4 T cell responses to
HPV16 E2 and E6 are measurable in some patients with regressing
cervical disease and are not seen in persistent infection (de et al., 2002;
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responses to E7 epitopes are found in patients with cervical cancer
though these are clearly unable to clear the disease (Oerke et al., 2005).
These data taken together suggest a controlling role for the nature and
the magnitude of the CD4 response to PV antigens in determining
clearance of HPV associated disease. Particular interest has been
focused on regulatory T cells of CD4+ CD25+ FoxP3+ phenotype within
cervical cancer (Adurthi et al., 2008), and on production of locally
immunoregulatory cytokines which might impact on cytotoxic T cell
function (Kobayashi et al., 2008). However the antigen speciﬁc T cells
responsible for control and clearance of HPV infection, the means by
which they achieve this, and the importance of regulatory T cells in
progression of HPV associated disease remains largely to be
established.
Induced immunity to HPV proteins and its impact on HPV
associated disease
Antibody
Immunoglobulins are soluble proteins displaying high afﬁnity
binding for a speciﬁc antigenic determinant produced by plasma cells
in tissues and lymph nodes. Once induced byexposure to their cognate
antigen, they continue to be produced at low level throughout life by
bonemarrowplasma cells. Antibodygenerally binds to conformational
determinants on structural components of a microorganism, and
assists with pathogen clearance or protects against reinfection by
promoting phagocytosis and by neutralising infectivity. Demonstra-
tion that the L1 major capsid protein of HPV could self assemble into
virus like particles (Zhou et al., 1991; Kirnbauer et al., 1993) and that
these could elicit host protective neutralising antibody enabled
development of vaccines (Lowy and Schiller, 2006) designed to
prevent HPV associated disease. These vaccines induce a polyspeciﬁc
antibody response which recognises a range of conformational
determinants on the viral capsid that are generally genotype speciﬁc.
In several phase three clinical trials vaccines have been shown effective
at preventing infection with the HPV types in the vaccine and
associated premalignant disease of the genital tract (Kahn and Burk,
2007a) for periods of up to ﬁve years in previously uninfected women.
Data on longer term protection, and on protection in men, are awaited
from ongoing clinical trials. Vaccines are only effective as prophylaxis
against infection (Hildesheim et al., 2007), and only give solid
protection against disease caused by the virus types they incorporate,
and therefore screening programs based on cytology or HPV testing
will continue as a secondary preventative measure for cervical cancer.
PV prophylactic vaccines are now licensed in over 100 countries
worldwide and routine immunisation programs introduced for pre-
teen girls in many of these. The vaccines have generally proven safe,
producing only local reactogenicity and occasional allergic reactions
(Brotherton et al., 2008). While capsid speciﬁc IgG antibody is
sufﬁcient to protect against HPV infection, as shown in passive transfer
studies (Suzich et al., 1995), and cervical secretions include signiﬁcant
amounts of transudated IgG (Nardelli-Haeﬂiger et al., 2003). Inhibition
byantibody of virus binding to target cells can be demonstrated in vitro
(Day et al., 2007), and in an in vivo mouse model antibody can block
conformational change likely necessary for virus entry into cells (Day
et al., 2008a). Nevertheless, the exactmechanism(s) bywhich antibody
protects against HPV infection at mucosal sites are uncertain.
The complexities of production of virus capsid based vaccines, and
their induction of predominantly type speciﬁc antibody, has led to
efforts to produce alternate host protective immunogens, and some are
currently in preclinical development. One strategy is based on produc-
tion of pentameric arrays of L1 capsid protein (Yuan et al., 2001) which
display many of the antigenic determinants of the natural virion.
Another strategy uses theL2minor capsidprotein as an immunogen that
displays some epitopes relatively conserved across virus types. Whilethese epitopes are subdominant in the intact L2 protein, their use as
epitope immunogens can induce reasonable titres of antibody, virus
neutralising in in vitromodels of PV infection (Alphs et al., 2008).
Cellular responses
Antigen speciﬁc effector T cell responses clear infection by release
of proinﬂammatory cytokines and chemokines which reinforce innate
effector mechanisms and by release of cytotoxic and pro-apoptotic
macromolecules to kill virus infected cells. Effector responses induced
by immunisation are relatively short lived, though they can be re-
called more rapidly upon rechallenge with antigen, and therefore
immunotherapy to induce antigen speciﬁc cellular responses is
designed for immediate therapy of persistent viral infection or of
cancer. Papillomavirus infected epithelial cells present non structural
proteins to the host immune system in the context of MHC Class I.
Class I restricted effector T cell responses can be generated in animal
models and in humans by immunisation with E7 protein with appro-
priate adjuvants, or with recombinant vectors encoding this protein,
reviewed in (Frazer, 2004). In animal models, transplantable tumours
expressing E7 can be cured by E7 speciﬁc immunotherapies, and
cure is dependent on induction of E7 speciﬁc cytotoxic T cells
(Feltkamp et al., 1993). E6 and E7 speciﬁc immunotherapeutics in
humans also induce antigen speciﬁc cellular immune responses
(Kenter et al., 2008), though evidence for efﬁcacy of the induced
immune responses against papillomavirus associated disease is
limited. The reasons for this apparent failure of appropriate cellular
immune responses to induce clinical remission is unclear, and may
include any or all of failed antigen presentation, induction of
inappropriate or inadequate effector responses, failed effector T cell
trafﬁcking to diseased tissues, or local immunoregulation.
Induced innate immunity as therapy in HPV infection
Local administration of proinﬂammatory stimuli inducing innate
immune responses, including the alpha interferons (Frazer and
McMillan, 1997) and the toll like receptor 7 agonist, imiquimod
(Wagstaff and Perry, 2007), has moderate efﬁciency as therapy for
genital warts. Induction of an innate effector mechanism is particu-
larly suggested by the failure of these therapies to promote
synchronous regression of untreated lesions, arguing against efﬁcacy
depending on induction of systemic antigen speciﬁc immunity.
The effect of viral proteins on the innate and adaptive
immune response
Papillomavirus infections are slow to induce measurable immune
responses and slow to clear, suggesting that papillomavirus may have
developed methods to evade host immune mechanisms. The primary
mechanism of viral immune evasion for PV infection is likely avoi-
dance of antigen presentation — absence of cell lysis and systemic
viremia minimises antigen availability for presentation, and also
ensures that few pro-inﬂammatory signals are given in the course of
infection to invoke adaptive immune responses. Expression of the
capsid proteins is limited to superﬁcial epithelial cells, a consequence
of codon usage optimised for expression in differentiated cells (Zhou
et al., 1999), and this is likely to reduce presentation of capsid proteins
to the immune system. The E7 and E6 nonstructural proteins of HPV
16 have pleiotropic activity on the biology of infected epithelial cells,
and particularly delay cell differentiation. Papillomavirus proteins also
apparently encode speciﬁc functions to inhibit immune responses,
though it should be considered that some loss of function of HPV
infected keratinocytes may reﬂect the impact of HPV proteins on
epithelial differentiation. Some speciﬁc anti-inﬂammatory and
immune inhibitory mechanisms are induced by HPV non-structural
proteins, including a blunting of the response to IFNα and IFNγ
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Chang and Laimins, 2000), and of expression of IRF-1, a key
intermediate transcription control factor for IFN induced effector
functions (Um et al., 2002). Such inhibition would be expected to
reduce speciﬁc antiviral defence mechanisms and also effective
presentation of antigen to the host immune system (Evans et al.,
2001; Nees et al., 2001; Ritz et al., 2001; Leggatt et al., 2002). There is
an E6 and E7 dependent reduction in secretion by KC of MIP3α,
impairing migration of Langerhans cells to the skin (Caberg et al.,
2008; Guess and McCance, 2005), of IL-8, a potent chemoattractant
(Huang and McCance, 2002), and of expression of TLR9, a key
proinﬂammatory signalling molecule (Hasan et al., 2007). E5 protein
enhances expression of gangliosides on cervical epithelial cells
(Suprynowicz et al., 2008), which might be expected to inhibit
cytotoxic T cell function locally, and reduces expression of MHC Class I
(Ashraﬁ et al., 2006), which might impair antigen presentation. There
are no known inhibitory effects of the viral structural proteins L1 or L2
or of the E1 and E4 non-structural proteins on immune responses
induced by infection with HPVs. Mutated L1 however may be able to
blunt any response of professional antigen presenting cells to the viral
capsid (Yang et al., 2005). Papillomaviruses thus live in equilibrium
with their mammalian hosts through a combination of immune
evasion and programmed immune suppression.
In conclusion, the majority of PV infections do not kill their host or
impair host reproductive ﬁtness. Lack of damage to host cells ensures a
minimal immune response from the host, enabling vegetative infections
that last months to years, with consequent opportunity for viral
infection to propagate to many new susceptible hosts. However,
intervention in this comfortable relationship by vaccination will have
the potential to signiﬁcantly reduce the burden of infection with
papillomaviruses in humankind, and the stable PV dsDNA genome will
hinder rapid viral evolution to evade the external threat to their niche
existence in host epithelial cells posed by vaccination.References
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